A Nature Communications paper described engineered exosome nanovesicles that deliver therapeutic antibodies directly to inflamed gastrointestinal tissue, demonstrating targeted activity in inflammatory‑bowel‑disease models. The delivery system leverages exosome tropism and surface engineering to enhance local retention and reduce systemic exposure. Authors and peer coverage framed the work as a potential route to improve safety and efficacy for biologic therapies in mucosal inflammatory diseases. Translational steps will require scalable exosome manufacturing and regulatory paths for biologically derived delivery vehicles, but the approach offers an alternative to systemic antibody dosing.